No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Hutchmed unveiled new details on its expanding oncology pipeline and research strategy, including the launch of its next-generation antibody-targeted therapy conjugate (ATTC) platform, during its annual research and development update on Monday.
The AIM-traded company said the ATTC approach could redefine precision oncology through a dual mechanism of action that combines antibody targeting with small-molecule inhibitor payloads.
It said its lead ATTC candidate, HMPL-A251, integrates a selective PI3K/PIKK inhibitor payload with a HER2-targeted antibody and had shown promising preclinical results.
Hutchmed said the treatment demonstrated strong efficacy and safety in both HER2-positive and HER2-low tumour models, performing comparably or better than existing therapies such as trastuzumab deruxtecan at equivalent doses.
The company said it expected to begin clinical development of HMPL-A251 in late 2025, evaluating the therapy across multiple cancer types.
"Our commitment to advancing innovative therapies drives HUTCHMED's mission to address critical unmet needs in oncology and immunology," said Dr Michael Shi, head of research and development and chief medical officer.
"The ATTC platform's potential to redefine precision oncology, combined with our robust pipeline and partnership strategy, positions us to deliver potentially transformative cancer and immunology treatments to patients around the world."
The company also highlighted progress across several late-stage clinical programmes.
Data from the FRUSICA-2 phase three study showed that fruquintinib in combination with sintilimab extended progression-free survival to 22.2 months in renal cell carcinoma, compared with 6.9 months for standard therapies.
Hutchmed said recruitment had completed for its SANOVO phase three study of savolitinib in first-line EGFR-mutated non-small cell lung cancer (NSCLC) in China, while enrollment in the global SAFFRON phase three trial remains on track for completion later this year.
The company added that its phase two and three trial of surufatinib for pancreatic cancer continued on schedule, with results from the phase two stage expected to be presented at an upcoming scientific meeting.
Meanwhile, preparations were underway to resubmit a new drug application for sovleplenib in immune thrombocytopenia in 2026, and topline data from a parallel study in autoimmune haemolytic anaemia were expected early next year.
Recruitment had also completed for a registrational phase two study of fanregratinib in intrahepatic cholangiocarcinoma in China, with a filing planned for the first half of 2026.
Hutchmed said its integrated pipeline and new ATTC platform supported its long-term goal of developing targeted and immuno-oncology therapies capable of addressing resistant and complex cancers across multiple markets.
At 1556 GMT, shares in Hutchmed China were up 3.18% at 227p.
Reporting by Josh White for Sharecast.com.